Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.
Egeler MD, Boomstra E, Rohaan MW, Van den Heuvel NMJ, Fraterman I, Delfos M, van de Poll-Franse LV, Borch TH, Svane IM, Haanen JBAG, Retèl VP, Boekhout AH. Egeler MD, et al. Among authors: van den heuvel nmj. J Cancer Surviv. 2023 Aug 22. doi: 10.1007/s11764-023-01452-8. Online ahead of print. J Cancer Surviv. 2023. PMID: 37606816
Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review.
Egeler MD, van Leeuwen M, Fraterman I, van den Heuvel NMJ, Boekhout AH, Lai-Kwon J, Wilthagen EA, Eriksson H, Haanen JB, Wilgenhof S, Ascierto PA, van Akkooi ACJ, van de Poll-Franse LV. Egeler MD, et al. Among authors: van den heuvel nmj. Crit Rev Oncol Hematol. 2023 Mar;183:103919. doi: 10.1016/j.critrevonc.2023.103919. Epub 2023 Feb 1. Crit Rev Oncol Hematol. 2023. PMID: 36736511 Review.
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, Pennington TE, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Rozeman EA, Klop WMC, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Torres Acosta A, Grijpink-Ongering LG, Gonzalez M, Jóźwiak K, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JBAG, Rawson RV, van de Wiel BA, van de Poll-Franse LV, Scolyer RA, Boekhout AH, Long GV, Blank CU. Reijers ILM, et al. Among authors: van den heuvel nmj. Nat Med. 2022 Jun;28(6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5. Nat Med. 2022. PMID: 35661157 Clinical Trial.
Thermoresponsive Complex Coacervate-Based Underwater Adhesive.
Dompé M, Cedano-Serrano FJ, Heckert O, van den Heuvel N, van der Gucht J, Tran Y, Hourdet D, Creton C, Kamperman M. Dompé M, et al. Among authors: van den heuvel n. Adv Mater. 2019 May;31(21):e1808179. doi: 10.1002/adma.201808179. Epub 2019 Mar 29. Adv Mater. 2019. PMID: 30924992
18 results